The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines [0.03%]
抗查克拉病毒广谱活性的抗病毒药物在宿主细胞系之间的效果不同
Evelyn J Franco,Jaime L Rodriquez,Justin J Pomeroy et al.
Evelyn J Franco et al.
Chikungunya virus (CHIKV) is a mosquito-borne virus that has recently emerged in the Western Hemisphere. Approved antiviral therapies or vaccines for the treatment or prevention of CHIKV infections are not available. This study aims to eval...
Corrigendum [0.03%]
勘误表
Galabov AS, Mukova L, Abashev YP, Wassilewa L, Tzvetkov P, Minkov V, Barinskiy IF, Ouzounov S, Sidzhakova D. Cycluridine: A novel antiviral effective against flaviviruses. Antivir. Chem. Chemother 2017; 25: 58-67. DOI: 10.1177/2040206617...
Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA [0.03%]
第30届国际抗病毒研究大会会议报告Atlanta, USA 美国亚特兰大
R Anthony Vere Hodge
R Anthony Vere Hodge
The 30th International Conference on Antiviral Research was held in Atlanta, GA, USA, from 21 to 25 May 2017. Each year, the International Society for Antiviral Research (ISAR) presents three major awards, this year to Mike Sofia (Elion awa...
Katherine Seley-Radtke,Jerome Deval
Katherine Seley-Radtke
Phosphoramidates and phosphonamidates (ProTides) with antiviral activity [0.03%]
具有抗病毒活性的磷酰胺酸酯和磷苯并氧氮杂环丁烷（ProTide）
Magdalena Slusarczyk,Michaela Serpi,Fabrizio Pertusati
Magdalena Slusarczyk
Following the first report on the nucleoside phosphoramidate (ProTide) prodrug approach in 1990 by Chris McGuigan, the extensive investigation of ProTide technology has begun in many laboratories. Designed with aim to overcome limitations a...
Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus [0.03%]
针对呼吸道合胞病毒疫苗和抗病毒药物检测的棉鼠模型
M S Boukhvalova,K C Yim,Jcg Blanco
M S Boukhvalova
Respiratory syncytial virus is the leading cause of pneumonia and bronchiolitis in infants and is a serious health risk for elderly and immunocompromised individuals. No vaccine has yet been approved to prevent respiratory syncytial virus i...
Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa [0.03%]
南非一线抗逆转录病毒治疗失败的HIV-1型C感染者中对利匹韦林频繁产生交叉耐药性
Kerri J Penrose,Chanson J Brumme,Maritsa Scoulos-Hanson et al.
Kerri J Penrose et al.
Background Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor...
Nucleosides for the treatment of respiratory RNA virus infections [0.03%]
用于呼吸道rna病毒感染的核苷类似物 лечения呼吸道rna病毒感染的核苷类药物治疗
Paul C Jordan,Sarah K Stevens,Jerome Deval
Paul C Jordan
Influenza virus, respiratory syncytial virus, human metapneumovirus, parainfluenza virus, coronaviruses, and rhinoviruses are among the most common viruses causing mild seasonal colds. These RNA viruses can also cause lower respiratory trac...
Characterization of phenyl pyrimidine derivatives that inhibit cytomegalovirus immediate-early gene expression [0.03%]
一类可抑制巨细胞病毒早期基因表达的苯基哒嗪衍生物的研究
Koh-Hei Yamada,Ryuichi Majima,Toyofumi Yamaguchi et al.
Koh-Hei Yamada et al.
Background Previously, we established a reporter cell line for human cytomegalovirus and screened anti-human cytomegalovirus compounds using the cell line. In this study, we characterized one of the identified compounds, 2,4-diamino-6-(4-me...
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses [0.03%]
核苷类似物作为针对节肢动物传播黄病毒的有效抗病毒剂的丰富来源
Luděk Eyer,Radim Nencka,Erik de Clercq et al.
Luděk Eyer et al.
Nucleoside analogs represent the largest class of small molecule-based antivirals, which currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis B or C viruses, and herpes viruses. High antiviral potency a...